Director, Regulatory and Research Partnerships

Hillary Stires serves as the Director, Regulatory and Research Partnerships at Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. For more than two decades, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.

At Friends, Hillary supports the development and implementation of the organization’s research and policy agenda. She uses her scientific and advocacy background to develop evidence based policies. Hillary collaborates with diverse teams to identify challenges in cancer research and create solutions that improve and accelerate cancer care for patients.

Prior to joining Friends, Hillary worked as a consultant at Avalere Health where she supported clients in navigating the regulatory strategy and FDA policy environment to improve market access. Hillary also provided clinical and scientific expertise to develop data driven research projects using Medicare and commercial claims data.

During her postdoctoral fellowship, Hillary became passionate about improving cancer research through establishing relationships between cancer researchers and patient advocates and talked about this work in podcasts, webinars, and a TEDx. Hillary worked as an Elevate Ambassador with the National Coalition for Cancer Survivorship to build programs to achieve this goal and continues to advocate for including the patient perspective in cancer research.

Hillary received her PhD in endocrinology and animal biosciences from Rutgers University and completed a postdoctoral fellowship in tumor biology at Georgetown University’s Lombardi Comprehensive Cancer Center where she was the recipient of a T32 Ruth L. Kirschstein Institutional National Research Service Award. Her research focused on tumor development and drug resistance in hormone dependent breast cancer.